Generation of live attenuated influenza virus by using codon usage bias

Journal of Virology

Volumn 89, Issue 21, 2015, Pages 10762-10773

  Fan, Rebecca L Y ^a   Valkenburg, Sophie A ^a   Wong, K S ^a   Li, Olive T W ^a   Nicholls, John M ^a   Rabadan, Raul ^b   Peiris, J S Malik ^a   Poon, Leo L M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; CODON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVIAN INFLUENZA VIRUS; CELLULAR IMMUNITY; CODON USAGE; CONTROLLED STUDY; EGG; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INFLUENZA A (H1N1); INFLUENZA A VIRUS (H1N1); INNATE IMMUNITY; MAMMAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEASONAL INFLUENZA; SINGLE DRUG DOSE; VIROGENESIS; VIRUS GENOME; VIRUS MUTATION; ZYGOTE; ANIMAL; BIOSYNTHESIS; CODON; DOG; GENETIC ENGINEERING; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; MDCK CELL LINE; MUTAGENESIS; PROCEDURES; VIROLOGY;

ANIMALS; CODON; DOGS; EGGS; GENETIC ENGINEERING; HEK293 CELLS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MADIN DARBY CANINE KIDNEY CELLS; MICE; MUTAGENESIS;

EID: 84945231559     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01443-15     Document Type: Article

References (39)

1. World Health Organization. 2012. Vaccines against influenza WHO position paper-November 2012. Wkly Epidemiol Rec 87:461-476.
2. Michiels B, Govaerts F, Remmen R, Vermeire E, Coenen S. 2011. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 29:9159-9170. http://dx.doi.org/10.1016/j.vaccine.2011.08.008.
3. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Petrie JG, McLean HQ, Belongia EA. 2015. Early estimates of seasonal influenza vaccine effectiveness-United States, January 2015. MMWR Morb Mortal Wkly Rep 64:10-15.
4. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:36-44. http://dx.doi.org/10.1016/S1473-3099(11)70 295-X.
5. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM, CAIV-T Comparative Efficacy Study Group. 2007. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356:685-696. http://dx.doi.org /10.1056/NEJMoa065368.
6. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. 2011. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 29:7733-7739. http://dx.doi.org/10.1016/j.vaccine.2011.07.128.
7. Yang LP. 2013. Recombinant trivalent influenza vaccine (FluBlok(R)): a review of its use in the prevention of seasonal influenza in adults. Drugs 73:1357-1366. http://dx.doi.org/10.1007/s40265-013-0103-6.
8. King JC, Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. 2009. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 27:6589 -6594. http://dx.doi.org/10.1016/j .vaccine.2009.08.032.
9. Beyer WEP, Palache AM, de Jong JC, Osterhaus ADME. 2002. Coldadapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20:1340-1353.
10. He X-S, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, Dekker CL, Greenberg HB, Arvin AM. 2006. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 80:11756 -11766. http://dx.doi.org/10.1128 /JVI.01460-06.
11. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC. 2009. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 361:1260-1267. http://dx.doi.org/10.1056/NEJMoa0808652.
12. Jin H, Lu B, Zhou H, Ma C, Zhao J, Yang C-F, Kemble G, Greenberg H. 2003. Multiple amino acid residues confer temperature sensitivity tohuman influenza virus vaccine strains (Flumist) derived from coldadapted A/Ann Arbor/6/60. Virology 306:18-24. http://dx.doi.org/10 .1016/S0042-6822(02)00035-1.
13. Plotkin JB, Kudla G. 2010. Synonymous but not the same: the causes and consequences of codon bias. Nat Rev Genet 12:32-42. http://dx.doi.org /10.1038/nrg2899.
14. Li ZP, Ying DQ, Li P, Li F, Bo XC, Wang SQ. 2010. Analysis of synonymous codon usage bias in 09H1N1. Virol Sin 25:329-340. http: //dx.doi.org/10.1007/s12250-010-3123-3.
15. Zhou T, Gu W, Ma J, Sun X, Lu Z. 2005. Analysis of synonymous codon usage in H5N1 virus and other influenza A viruses. Biosystems 81:77-86. http://dx.doi.org/10.1016/j.biosystems.2005.03.002.
16. Wong EH, Smith DK, Rabadan R, Peiris M, Poon LL. 2010. Codon usage bias and the evolution of influenza A viruses. Codon usage biases of influenza virus. BMC Evol Biol 10:253. http://dx.doi.org/10.1186/1471 -2148-10-253.
17. Goni N, Iriarte A, Comas V, Sonora M, Moreno P, Moratorio G, Musto H, Cristina J. 2012. Pandemic influenza A virus codon usage revisited: biases, adaptation and implications for vaccine strain development. Virol J 9:263. http://dx.doi.org/10.1186/1743-422X-9-263.
18. Jenkins GM, Holmes EC. 2003. The extent of codon usage bias in human RNA viruses and its evolutionary origin. Virus Res 92:1-7. http://dx.doi .org/10.1016/S0168-1702(02)00309-X.
19. Hershberg R, Petrov DA. 2008. Selection on codon bias. Annu Rev Genet 42:287-299. http://dx.doi.org/10.1146/annurev.genet.42.110807.091442.
20. Aragones L, Guix S, Ribes E, Bosch A, Pinto RM. 2010. Fine-tuning translation kinetics selection as the driving force of codon usage bias in the hepatitis A virus capsid. PLoS Pathog 6:e1000797. http://dx.doi.org/10 .1371/journal.ppat.1000797.
21. Aragones L, Bosch A, Pinto RM. 2008. Hepatitis A virus mutant spectra under the selective pressure of monoclonal antibodies: codon usage constraints limit capsid variability. J Virol 82:1688-1700. http://dx.doi.org/10 .1128/JVI.01842-07.
22. Mueller S, Papamichail D, Coleman JR, Skiena S, Wimmer E. 2006. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J Virol 80:9687-9696. http://dx.doi.org/10.1128/JVI .00738-06.
23. Coleman JR, Papamichail D, Skiena S, Futcher B, Wimmer E, Mueller S. 2008. Virus attenuation by genome-scale changes in codon pair bias. Science 320:1784-1787. http://dx.doi.org/10.1126/science.1155761.
24. Yang C, Skiena S, Futcher B, Mueller S, Wimmer E. 2013. Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice. Proc Natl Acad Sci U S A 110:9481-9486. http://dx.doi.org/10.1073/pnas.1307473110.
25. Nogales A, Baker SF, Ortiz-Riano E, Dewhurst S, Topham DJ, Martinez-Sobrido L. 2014. Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development. J Virol 88:10525-10549. http://dx.doi.org/10.1128/JVI.01565-14.
26. Mueller S, Coleman JR, Papamichail D, Ward CB, Nimnual A, Futcher B, Skiena S, Wimmer E. 2010. Live attenuated influenza virus vaccines by computer-aided rational design. Nat Biotechnol 28:723-726. http://dx .doi.org/10.1038/nbt.1636.
27. Moss WN, Priore SF, Turner DH. 2011. Identification of potential conserved RNA secondary structure throughout influenza A coding regions. RNA 17:991-1011. http://dx.doi.org/10.1261/rna.2619511.
28. Gog JR, Afonso Edos S, Dalton RM, Leclercq I, Tiley L, Elton D, von Kirchbach JC, Naffakh N, Escriou N, Digard P. 2007. Codon conservation in the influenza A virus genome defines RNA packaging signals. Nucleic Acids Res 35:1897-1907. http://dx.doi.org/10.1093/nar/gkm087.
29. Lamb RA, Takeda M. 2001. Death by influenza virus protein. Nat Med 7:1286-1288. http://dx.doi.org/10.1038/nm1201-1286.
30. Priore SF, Moss WN, Turner DH. 2012. Influenza A virus coding regions exhibit host-specific global ordered RNA structure. PLoS One 7:e35989. http://dx.doi.org/10.1371/journal.pone.0035989.
31. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 97:6108-6113. http://dx.doi.org/10 .1073/pnas.100133697.
32. Xu L, Bao L, Li F, Lv Q, Ma Y, Zhou J, Xu Y, Deng W, Zhan L, Zhu H. 2011. Adaption of seasonal H1N1 influenza virus in mice. PLoS One 6:e28901. http://dx.doi.org/10.1371/journal.pone.0028901.
33. Brown E, Liu H, Kit LC, Baird S, Nesrallah M. 2001. Pattern of mutation in the genome of influenza A virus on adaptation to increased virulence in the mouse lung: identification of functional themes. Proc Natl Acad Sci U S A 98:6883-6888. http://dx.doi.org/10.1073/pnas.111165798.
34. Poon LL, Leung YH, Nicholls JM, Perera PY, Lichy JH, Yamamoto M, Waldmann TA, Peiris JS, Perera LP. 2009. Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. J Immunol 182:3063-3071. http://dx.doi .org/10.4049/jimmunol.0803467.
35. Valkenburg SA, Li OTW, Mak PWY, Mok CKP, Nicholls JM, Guan Y, Waldmann TA, Peiris JSM, Perera LP, Poon LLM. 2014. IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+T cells for heterosubtypic protection. Proc Natl Acad Sci U S A 111:5676-5681. http://dx.doi.org/10.1073/pnas.1403684111.
36. Wen X, Huang X, Mok BW-Y, Chen Y, Zheng M, Lau S-Y, Wang P, Song W, Jin D-Y, Yuen K-Y, Chen H. 2014. NF90 exerts antiviral activity through regulation of PKR phosphorylation and stress granules in infected cells. J Immunol 192:3753-3764. http://dx.doi.org/10 .4049/jimmunol.1302813.
37. Blaschke V, Reich K, Blaschke S, Zipprich S, Neumann C. 2000. Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells: validation of a new real-time RT-PCR technology. J Immunol Methods 246:79-90. http://dx.doi.org/10.1016/S0022-1759(00)00304-5.
38. Nicholls JM, Wong LPW, Chan RWY, Poon LLM, So LKY, Yen H-L, Fung K, van Poucke S, Peiris JSM. 2012. Detection of highly pathogenic influenza and pandemic influenza virus in formalin fixed tissues by immunohistochemical methods. J Virol Methods 179:409-413. http://dx .doi.org/10.1016/j.jviromet.2011.11.006.
39. Maassab H. 1969. Biologic and immunologic characteristics of coldadapted influenza virus. J Immunol 102:728-732.